Alzheimer’s drug may benefit some patients, new data shows
Jason Karlawish of the Perelman School of Medicine says that the new data on experimental Alzheimer’s drug lecanemab show reason for both optimism and caution.
・ From The New York Times
4/22
Jason Karlawish of the Perelman School of Medicine says that the new data on experimental Alzheimer’s drug lecanemab show reason for both optimism and caution.
・ From The New York Times